PenkeTrading Posted - 2 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Nyxoah. Is that bullish or bearish? $NYXH #Nyxoah #RsiOversold #NASDAQ

Monkey_Banana_Genius Posted - 1 week ago

$NYXH new med tech company with minimally invasive surgical alternative to CPAP for OSA. Some competition for $INSP. 🤔. Starter in NYXH to monitor.

Thestocktraderhubzee Posted - 2 weeks ago

WATCHLIST NOV 06 2024.. $NYXH Cantor Fitzgerald Reiterates Overweight on Nyxoah, Maintains $16 Price Target $EVEX Cantor Fitzgerald Reiterates Overweight on Eve Holding, Maintains $5 Price Target $CTOS Oppenheimer Maintains Outperform on Custom Truck One Source, Lowers Price Target to $5 $EDIT RBC Capital Maintains Sector Perform on Editas Medicine, Lowers Price Target to $5 $ALL Wells Fargo Maintains Equal-Weight on Allstate, Raises Price Target to $186

LoyalShark Posted - 2 weeks ago

$NSPR Just seeing $NYXH has its price target raised to $16 by Cantor Fiitzgerald. They make Sleep Apnea with a platform called Genio that is CE- mark validated. Revs are $4.79 million expected '24 Mrkt Cap $305.81 Million. Losing money every day. Compare it to NSPR. Let me know what your thoughts on as to why $NYXH would have a higher valuation than NSPR. Compare their numbers - ratios. Maddening NSPR would be SUCKING air due to an incompaetent CEO's approach to creting a following. WHY would $NYXH have 7 analysts following and $NSPR have ONE ...that was paid to be there. Why would they get a MUCH higher valuation based on sales, cash flow, ebitda etc. Its the difference of a PUBLIC MARKET know how. Public Market IQ. When you suck at it -- you suck at it. NSPR's CEO sucks at it.

themacromindset Posted - 1 month ago

$NYXH Nyxoah Raises $27 Million through its At-the-Market Offering

DonCorleone77 Posted - 1 month ago

$NYXH Nyxoah raises $27M through at-the-market offering Nyxoah SA "announced that the Company has sold 3.0 million shares raising $27.0 million in gross proceeds pursuant to the Company's $50 million at-the-market offering at a price per share equal to the market price on the Nasdaq Global Market at the time of sale. The shares were sold, based on interest received, to a single U.S.-based healthcare investor. Cantor Fitzgerald & Co. is acting as the sales agent for the ATM offering."

_www_larval_com_ Posted - 1 month ago

$NYXH has reversed 4% higher to 0% (~3Mv) moments ago, follow for more volatility.

DogStarGlobal Posted - 09/29/24

$NYXH Nyxoah

jParkz Posted - 09/27/24

$NYXH News DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update https://marketwirenews.com/news-releases/dream-pivotal-study-data-presented-at-the-internatio-4728957683132987.html $NYXH

Stock_Titan Posted - 09/27/24

$NYXH Publication relating to transparency notifications https://www.stocktitan.net/news/NYXH/publication-relating-to-transparency-cboi0es5giof.html

Stock_Titan Posted - 2 months ago

$NYXH Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device https://www.stocktitan.net/news/NYXH/nyxoah-rings-the-closing-bell-at-nasdaq-while-preparing-for-u-s-8pqc1dtrmaof.html

Thestocktraderhubzee Posted - 3 months ago

$NYXH HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $18 Price Target

Stock_Titan Posted - 3 months ago

$NYXH Nyxoah Reports Second Quarter and First Half 2024 Financial and Operating Results https://www.stocktitan.net/news/NYXH/nyxoah-reports-second-quarter-and-first-half-2024-financial-and-k7wzvh1d24ke.html

Stock_Titan Posted - 07/29/24

$NYXH Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 https://www.stocktitan.net/news/NYXH/nyxoah-to-release-second-quarter-and-first-half-2024-financial-e2fcvli4xt0k.html

chaostrader Posted - 4 months ago

$NYXH Part of the loan agreement, Nyxoah will grant the EIB 468,384 synthetic warrants with a strike price of €8.11. These warrants are exercisable after five years or in exceptional situations, allowing the EIB to receive cash based on Nyxoah's stock performance​. https://www.pharmiweb.com/press-release/2024-07-03/nyxoah-has-signed-a-375-million-loan-facility-agreement-with-the-european-investment-bank

Moondusterke2 Posted - 4 months ago

$NYXH **

OpenOutcrier Posted - 4 months ago

$NYXH (+2.1% pre) Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank https://ooc.bz/l/36861

Stock_Titan Posted - 4 months ago

$NYXH Nyxoah Has Signed a €37.5 Million Loan Facility Agreement with the European Investment Bank https://www.stocktitan.net/news/NYXH/nyxoah-has-signed-a-eu37-5-million-loan-facility-agreement-with-the-zy8nmuhtx7uk.html

Stock_Titan Posted - 4 months ago

$NYXH Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA https://www.stocktitan.net/news/NYXH/nyxoah-submits-fourth-and-final-module-in-pma-application-for-genio-s97mfyfzhrnu.html

AnaChart Posted - 06/24/24

$NYXH https://anachart.com/wp-content/uploads/ana_temp/1719234125_soc-img.jpg

DonCorleone77 Posted - 06/24/24

$INSP $NYXH $LLY Inspire Medical price target lowered to $170 from $210 at Stifel Stifel analyst Jonathan Block lowered the firm's price target on Inspire Medical (INSP) to $170 from $210 and keeps a Hold rating on the shares. Additional data from Eli Lilly's (LLY) SURMOUNT-OSA trial that was released late Friday afternoon raises more questions for Inspire Medical and the HGNS market than it offers answers, the analyst tells investors. The incremental information, notably the percent of obstructive sleep apnea, or OSA, patients no longer considered moderate or severe at week 52, makes the firm "more concerned on out-year numbers," and it lowered estimates and targets for both Inspire and Nyxoah (NYXH), the analyst added.

Americanbulls Posted - 5 months ago

$NYXH apparently the bear pattern is not confirmed. Prices continue to rise. www.Americanbulls.com/SignalPage.aspx?lang=en&Ticker=NYXH

Stock_Titan Posted - 5 months ago

$NYXH Publication relating to transparency notifications https://www.stocktitan.net/news/NYXH/publication-relating-to-transparency-peo6f27ubcdn.html

TheDizPlinTrader Posted - 05/25/24

$NYXH slightly below where it should be, but a green finish is promising! I will come back and asses the situation with new levels soon. Have a lovely weekend! David.

Celz Posted - 05/24/24

$NYXH

TheDizPlinTrader Posted - 05/24/24

$NYXH Daily Analysis: 1-Hour Support & Resistance Zones 🚀 Current Price: $8.64 🔹 Support Levels: Immediate support at $8.65 (Just broke) Stronger support at $8.50 🔸 Resistance Levels: Immediate resistance at $8.90 Longer-term resistance at $9.05 📊 Watch these key levels for potential trading opportunities! Stay disciplined! ⚔️

DonCorleone77 Posted - 05/23/24

$NYXH Nyxoah 5.374M share Spot Secondary priced at $9.25 Cantor Fitzgerald acted as lead book running manager for the offering.

Stock_Titan Posted - 05/23/24

$NYXH Nyxoah Announces Pricing of Offering https://www.stocktitan.net/news/NYXH/nyxoah-announces-pricing-of-ybisb9v9zp4a.html

OpenOutcrier Posted - 05/23/24

$NYXH (-9.1% pre) Nyxoah Announces Proposed Offering of Ordinary Shares - GN https://ooc.bz/l/33802

DonCorleone77 Posted - 05/22/24

$NYXH Nyxoah files ordinary shares offering, no amount given Nyxoah announced the commencement of a proposed underwritten public offering in the United States, which may include shares sold in a private offering to certain qualified or institutional investors outside the United States, including within the European Union. All of the ordinary shares are being offered by Nyxoah and there are no selling stockholders in the proposed offering. Nyxoah intends to use the net proceeds from the proposed offering (i) for pre-commercialization and commercialization activities in the United States; (ii) to continue gathering clinical data and to support physician initiated clinical research projects related to OSA patient treatments; (iii) to further finance research and development activities related to the next generation of the Genio system and to continue to build a pipeline of new technologies and explore potential collaboration opportunities in the field of monitoring and diagnostics for OSA; and (iv) for other general corporate purposes, including, but not limited to, working capital, capital expenditures, investments, acquisitions, should the Company choose to pursue any, and collaborations. Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering. Degroof Petercam is acting as a co-manager.